Patterns and Predictors of Recurrence After Curative Resection of Colorectal Liver Metastasis (CRLM)

Our study aims to determine the predictors and patterns of relapses after curative colorectal liver metastasis (CRLM) resection.

A single-centre, retrospective study of CRLM patients operated between 2010 and 2022 was performed. The site of first recurrence was either hepatic (marginal (≤ 1 cm) or extramarginal), extrahepatic, or both. Factors that predicted relapse patterns and overall survival were determined by multivariable Cox regression analysis with backward elimination of variables.

The study consisted of 258 patients, with a similar proportion of synchronous (144; 56%) and metachronous(114; 43%) metastasis. At a 43-month median follow-up, 156 patients (60.4%) developed recurrences with 33 (21.1%) in the liver, 62(24.03%) extra-hepatic recurrences, and 58 (22.48%) having both. Isolated marginal liver relapses were seen in seven (9.89%) liver recurrence patients. The median overall and relapse-free survivals were 38 months (30–54) and 13 months (11–16), respectively. The 3-year liver-relapse-free survival was 54.4% (44.9–60.6). Size of liver metastases > 5 cm (HR 2.06 (1.34–3.17), involved surgical margins (HR 2.16 (1.27–3.68)), and adjuvant chemotherapy (HR 1.89 (1.07–3.35)) were predictors of hepatic recurrences. Node positivity of primary (HR 1.61 (1.02–2.56)), presence of baseline extra-hepatic metastases (HR 0.30 (0.18–0.51)), size of liver metastases > 5 cm (HR 2.02 (1.37–2.99)), poorly differentiated histology (HR 2.25 (1.28–3.49)), presence of LVI (HR 2.25 (1.28–3.94)), and adjuvant chemotherapy (HR 2.15 (1.28–3.61)) were predictors of extra-hepatic recurrences.

The study found majority relapses occurred at extrahepatic sites whilst isolated marginal recurrences were few. The consistent predictors of recurrence were size and inability to deliver adjuvant therapy. A tailored adjuvant therapy might improve outcomes after liver metastasectomy in colorectal cancers.